Showing 3591-3600 of 19355 results for "".
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/Join us to learn about the emerging data with VMAT2 inhibitors for the treatment of tardive dyskinesia.CKD-aP or Something Else? Decoding the Diagnosis
https://reachmd.com/programs/cme/ckd-ap-or-something-else-decoding-the-diagnosis/36296/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Elevating CKD-aP Care: New Frontier
https://reachmd.com/programs/cme/elevating-ckd-ap-care-new-frontier/36298/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
https://reachmd.com/clinical-practice/oncology-hematology/keynote-717-randomized-phase-2-trial-of-adding-local-hypofractionated-radiotherapy-to-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-cancer/39778/In the phase 2 KEYNOTE-717 trial, adding local hypofractionated radiotherapy to pembrolizumab improved systemic response rates in recurrent or metastatic HNSCC.Exosome Therapy for Pelvic Tissue Regeneration
https://reachmd.com/ma-issues-index/september-october-2025/exosome-therapy-for-pelvic-tissue-regeneration/39268/Preclinical studies highlight potential applications for vaginal mesh complications, anal sphincter injury, and urinary incontinenceTreatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-a-pathophysiology-driven-framework-leveraging-fcrn-therapeutics/29537/A paradigm shift embracing targeted inhibitors of the neonatal Fc receptor (FcRn) is improving patient outcomes in gMG. Do you know how? Learn here!Advances in MS Management: Current and Future Directions
https://reachmd.com/programs/neurofrontiers/advances-in-ms-management-current-and-future-directions/26387/Read about a recent review article that provided critical insights on the pathophysiology, diagnosis, and treatment of multiple sclerosis.Not Just a Headache: Migraine Across Women’s Lifespan
https://reachmd.com/programs/cme/not-just-a-headache-migraine-across-womens-lifespan/36591/Review hormonal, diagnostic, and treatment considerations for migraine across women's life stages, including menstrual and menopausal transitions.Expert Recommendations and Key Takeaways
https://reachmd.com/programs/cme/expert-recommendations-and-key-takeaways/36186/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Heart Failure Grand Rounds: 3 Things You Need to Know About Cardiac Contractility Modulation
https://reachmd.com/programs/cme/heart-failure-grand-rounds-3-things-you-need-to-know-about-cardiac-contractility-modulation/14396/What can you do when GDMT isn’t working? Learn about CCM, an implantable device-based therapy that’s improving symptoms and QoL in patients with HF.